Earlier this year, Horizon announced a new collaboration and license agreement with Mammoth Biosciences.
Eli Lilly recently announced plans to postpone most new COVID-19-unrelated study starts.
The long-standing competition is now open for entry to pharma marketers in a variety of roles and experience levels.
Sense Biodetection has also pitched in, announcing an accelerated programme to launch the world’s first instrument-free, point-of-care molecular diagnostic test for the novel virus.
The approval was based on the Phase III CASPIAN trial, in which the risk of death was reduced by 27%.
The European authorisation is based on the Phase III ARAMIS trial.
However, the company has decided to postpone the initiation of Part B due to concerns regarding the COVID-19 pandemic.
Acute coronary syndrome is a type of cardiovascular disease that occurs when a blood clot forms.
Vertex has also revealed its plans to keep clinical trials going during the unstable time.
The meeting was held virtually to help limit the spread of COVID-19.